UNSPSC 51171820: Dimenhydrinate

This classification denotes an antimuscarinic agent and antiemetic agent with the molecular formula C17H21NO.C7H7ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JB937PER5C, chemically known as 8-chlorotheophylline, compound with 2-(diphenylmethoxy)-n,n-dimethylethylamine (1:1) but generally known as dimenhydrinate, which bears US NIH Compound Identifier 10660. European Medicines Agency schedules Dimenhydrinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07159MIG.

UNSPSC 51171820 Dimenhydrinate is a Commodity code that captures pharmaceutical products procured by state and local health and criminal justice agencies, though recent activity shows limited direct solicitation specifically for this drug ingredient. The recent opportunities tagged to this code involve broader pharmaceutical and drug-testing services rather than dimenhydrinate itself: a Collin County, Texas community supervision department seeking offender drug-testing services (RFP 2026-327, due July 23, 2026, estimated value $600,000); a Texas Health and Human Services Commission RFI gathering market intelligence on direct-to-manufacturer prescription programs; and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon (RFP S1070000015802, due March 26, 2026). The issuing bodies include county criminal justice departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The scope involves screening and confirmatory drug testing, pharmacy benefit management through direct manufacturer relationships, and generic pharmaceutical supply agreements with specific pricing and NDC coding requirements.

Geographic activity centers on Texas and the upper Midwest (Minnesota and Oregon), with MMCAP's multi-state model spanning broader participation. The representative opportunities show a shift toward service-based testing and pharmacy management rather than discrete ingredient procurement. Collin County's testing contract requires vendors to maintain SAMHSA or CAP lab certification and deliver results on a per-test basis (approximately 25,031 tests annually at roughly $24 per test under the estimated budget); the MMCAP RFP emphasizes competitive pricing on established generic drugs with cGMP and DSCSA compliance. Neither solicitation names dimenhydrinate as a specified product, suggesting the code may be broadly applied to pharmaceutical categories rather than this specific antihistamine. Prospective vendors should monitor cooperative purchasing vehicle activity and state health commission RFPs for indirect demand signals, as dimenhydrinate typically appears in state formularies and institutional bulk-purchase agreements rather than as a standalone procurement target.